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1. Introduction 
The American Cancer Society reports that ~261,100 new cases of invasive and in situ breast 
cancer were diagnosed in 2010, and nearly 40,000 fatalities were attributed to this disease 
(American Cancer Society, 2010). Although death rates have steadily decreased since 1990, 
breast cancer currently ranks second in cancer deaths among women. Improvements in 
detection, treatment, and prevention education contribute to slow the incidence rate, and 
rapidly evolving nuclear medicine techniques have emerged as a formidable opponent to 
female breast cancer. The involvement of nuclear medicine imaging modalities in both the 
detection and diagnosis of breast cancer has increased in recent years (Gopalan et al., 2002). 
In contrast to earlier imaging methods, in which the transmission of various forms of energy 
through tissue is employed to generate an image, nuclear medicine imaging techniques are 
based on detection of the energy emitted from radioactive tracers that are injected into the 
body and subsequently accumulate locally in specific tissues (Nass et al., 2001). The 
classification of these techniques as either positron emission tomography (PET) or single 
photon emission computed tomography (SPECT) imaging modalities is determined by the 
radionuclide that is utilized to synthesize a given radiotracer. 
The theory behind nuclear medicine imaging techniques to detect and diagnose breast 
cancer is founded on preferential radiopharmaceutical uptake by cancerous cells as a 
result of alterations in metabolic rate, vascularity, or receptor expression which are 
associated with malignancy. Although both PET and SPECT are commonly employed to 
detect a variety of malignancies, neither imaging technique has achieved clinical 
acceptance as a method of imaging breast cancer due to the lack of sensitivity and 
specificity demonstrated by available radiotracers (Gopalan et al., 2002; Nass et al., 2001; 
Rosen et al., 2008). 
Presently, there is only one radiopharmaceutical, the SPECT imaging agent technetium-99m 
methoxy-isobutyl-isonitrile (99mTc-sestamibi, Miraluma®), that has received FDA approval 
for use as a diagnostic adjunct to mammography (Gopalan et al., 2002; Nass et al., 2001; 
Rosen et al., 2008). Although the mechanism governing the concentration of 99mTc-sestamibi 
in cancer cells is not fully understood, it may be related to the degree of cellular proliferation 
and vascular permeability (Nass et al., 2001). Once inside malignant cells, 99mTc-sestamibi is 
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sequestered within the cytoplasm as a result of the strong electrostatic attraction between 
the positively charged lipophilic 99mTc-sestamibi and the negatively charged mitochondria. 
This sequestration allows for the accumulation of 99mTc-sestamibi in cancer cells over 
time, presenting with high contrast on the resulting SPECT image (Gopalan et al., 2002). 
Despite the relatively high overall sensitivity (75-95%), specificity (71-100%), positive 
predictive value (67-100%), and accuracy (67-92%) demonstrated in numerous trials, 
99mTc-sestamibi has proven unsuitable for the diagnosis of lesions smaller than 12 
millimeters due to a significant decrease in both sensitivity (30-50%) and specificity (50%) 
(Gopalan et al., 2002). 
2. Current research: Toward receptor-targeted radiopharmaceuticals 
The continued interest in the development of radiopharmaceuticals for the detection and 
diagnosis of breast cancer is based on the fact that current methods fail to both detect and 
accurately diagnose early stage lesions in a large percentage of patients (Berghammer et al., 
2001; Gopalan et al., 2002; Olsen & Gotzsche 2001). Nuclear medicine imaging techniques 
are well suited to address this situation given their ability to noninvasively detect a variety 
of physiological alterations associated with malignancy. The potential clinical applications 
of scintigraphic evaluation of breast cancer patients fall into five categories: 1) the early 
detection of breast cancer, 2) the differentiation between benign and malignant masses,  
3) the staging of newly discovered breast cancer, 4) the detection of distant metastatic sites, 
and 5) the evaluation of tumor response to therapy (Berghammer et al., 2001; Rosen et al., 
2008). 
2.1 Early radiopharmaceuticals 
While radiolabeled small molecules have accounted for the vast majority of imaging agents 
initially investigated for breast cancer detection and diagnosis, their non-specificity has 
resulted in low accumulation in target tissues, high levels of background radioactivity, and 
poor image resolution (Anderson & Welch, 1999). As a consequence of these findings, 
research efforts have shifted towards the utilization of monoclonal antibodies, which have 
been designed to target specific antigens that are over-expressed on tumor cells (Signore et 
al., 2001). 
However, radiolabeled monoclonal antibodies have had limited clinical success due to 
several factors including the immunogenicity of the murine antibodies frequently employed 
in radiotracer preparation, the predominately hepatobiliary route of excretion, and the 
reduced ability to extravasate and access the target antigen as a result of the large size of 
intact monoclonal antibodies (Blok et al., 1999).Although the introduction of Fab´ and F(ab)2´ 
fragments, chimeric, and humanized antibodies have diminished these effects, accumulation 
of monoclonal antibodies in tumor tissue continues to be insufficient, generating 
unfavorable target to background ratios.The advent of radiolabeled biologically active 
peptides in the early 1990s provided a means to overcome the limitations associated with 
these early radiopharmaceuticals (Table 1) (Fischman et al., 1993).The unique over-
expression of specific receptors on malignant cells allows for their selective targeting using 
radiolabeled peptides that are designed to act as ligands for these receptors 
(Katzenellenbogen et al., 1995). A number of these receptor targets that are described herein 
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have been identified on breast cancer cells, including those for somatostatin, vasoactive 
intestinal peptide, neuropeptide Y, and gastrin releasing peptide. 
 
 Small Molecules Monoclonal Antibodies Peptides 
Synthesis Facile Lengthy Facile 
Size 
Less than 
1,500Da 
MAb: ~160kDa, 
Fab´ and F(ab)2´ 
Fragments: 10-100kDa 
Less than 
10,000Da 
Specificity Moderate 
High, 
Inflammation Sites: 
Nonspecific IgG uptake 
High 
Binding Affinity 
Perfusion Agents: 
N/A, 
Others: Moderate 
High High 
In Vivo Binding 
Perfusion Agents: 
N/A, 
Others: Moderate 
Limited by size High 
Target to 
Background Ratio 
Moderate Moderate 
Moderate to 
High 
Blood Clearance Variable Slow Rapid 
Immunogenicity No 
Potential for HAMA 
response 
No 
Table 1. Comparison of Early Radiopharmaceuticals (Blok et al., 1999; Fischman et al., 1993; 
Signore et al., 2001) 
2.2 Somatostatin receptor scintigraphy 
Somatostatin (SST) is a peptide hormone with two endogenous forms, SST-14 and SST-28, 
which are the cleavage products of the SST prohormone. SST may be found in several organ 
systems, including the central nervous system, the hypothalamopituitary system, the 
gastrointestinal tract, the exocrine and endocrine pancreas, and the immune system. This 
widespread distribution highlights the varied actions of SST throughout the body, ranging 
from inhibition of peptide hormone secretion to modulation of neurotransmission to 
inhibition of cellular proliferation. These effects are mediated via interaction with G protein-
coupled SST receptors, which may lead to a number of intracellular actions including the 
inhibition of the adenylyl cyclase-cAMP-protein kinase A and MAP kinase (MAPK) 
pathways, modulation of potassium channels, stimulation of phopholipase A2, and 
activation of phosphotyrosine phosphatases. To date, five SST receptor subtypes have been 
identified (SSTR1, SSTR2, SSTR3, SSTR4, SSTR5), which differ in both their expression pattern 
and their affinity for structural analogs of SST (Pomper & Gelovani, 2008; Reubi, 2008). 
The observation that the administration of SST inhibits the growth of various tumor cell 
lines as a result of their over-expression of the SST receptor led to the development of 
OctreoScan® (111In-diethylenetriaminepentaacetic acid (DTPA)-octreotide), a radiolabeled 
synthetic SST analog that became the first peptide-based radiopharmaceutical to receive 
FDA approval for the scintigraphic localization of SST receptor-positive neuroendocrine 
tumors. Due to the fact that endogenous SST exhibits a short in vivo half-life as a result of 
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rapid degradation by both aminopeptidases and endopeptidases, OctreoScan® incorporates 
modified amino acids into the Phe-(D)Trp-Lys-Thr receptor binding motif of octreotide to 
inhibit its metabolism and allow for increased tumor uptake. 
The discovery that SST receptors are expressed on a multitude of tumor types, including 
those of the breast (50-75%), coupled with the diagnostic and therapeutic success of 
OctreoScan® in patients with neuroendocrine carcinomas, generated interest in the potential 
expansion of OctreoScan®’s clinical use. While the successful scintigraphic detection of both 
primary and metastatic breast cancer has been reported with OctreoScan® in 50 to 94% of 
breast cancer cases, these figures may represent an overestimation as nonspecific uptake by 
nonmalignant breast tissue is observed in 15% of patients (Bajc et al., 1996; Reubi, 2008; 
Wang et al., 2008). In addition to the nonspecific uptake observed with OctreoScan®, the low 
density of SST receptors (SSTR2A and SSTR5) present in carcinomas of the breast combined 
with their heterogeneous expression pattern have prevented the acceptance of this agent for 
the routine diagnosis of breast cancer. 
2.3 Vasoactive intestinal peptide scintigraphy 
Vasoactive intestinal peptide (VIP) is a neuropeptide composed of 28 amino acids that 
belongs to the glucagon secretion family of peptides. VIP, and the closely related pituitary 
adenylate cyclase-activating polypeptide (PACAP), are among the most important 
neurotransmitters employed in the digestive system. In addition to its actions in the gut, VIP 
has a modulatory role in both the central nervous and immune systems. These actions are 
mediated by binding to G protein-coupled VIP receptors (VPAC1, VPAC2), which may be 
internalized after ligand binding, resulting in various intracellular effects including 
stimulation of adenylyl cyclase activity (Pomper & Gelovani, 2008; Reubi, 2008). The VPAC1 
and VPAC2 receptors exhibit distinct distribution patterns, with preferential expression of 
the VPAC1 receptor in a number of tissues including hepatocytes, gastrointestinal mucosa, 
pancreatic ducts, lung acini, thyroid follicles, prostatic glands, bladder and ureter 
urothelium, and breast lobules and ducts and of the VPAC2 receptor in smooth muscle. In 
addition to its ubiquitous in vivo biodistribution pattern, the VPAC1 receptor has been 
reported to be expressed in up to 93% of all primary tumors and metastatic sites of lung and 
breast cancer, generating interest in the development of VPAC1-targeted radiotracers that 
may be employed in the detection and diagnosis of various neoplasms (Moody & Gozes, 
2007; Pomper & Gelovani, 2008; Reubi, 2008). 
Radiopharmacological targeting of the VPAC1 receptor in colon cancer tumors was initially 
accomplished by radiolabeling native VIP with iodine-123 (123I). While promising 
scintigraphic images have been obtained using this agent, the rapid in vivo degradation of 
endogenous VIP, combined with both the cost and the difficulty associated with 123I-VIP 
conjugate synthesis, have hindered widespread clinical use of this compound. In an effort to 
address these issues, investigators have constructed a variety of VIP analogs that are 
suitable for labeling with a number of radioisotopes including technetium-99m (99mTc), 
copper-64 (64Cu), and fluorine-18 (18F) (Moody & Gozes, 2007; Pomper & Gelovani, 2008; 
Thakur et al., 2004). Although these radiotracers have proven capable of in vivo targeting of 
VPAC1 receptor-bearing tumors, the significant background radioactivity that is present as a 
result of ubiquitous VPAC1 receptor expression and the rapid in vivo degradation of these 
VIP analogs reduces the resolution of the images obtained. These results, coupled with the 
fact that VPAC1 receptors are found in high (>2,000 dpm/mg tissue) density in only 37% of 
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breast tumors, suggest that radiolabeled VIP conjugates are unlikely to gain widespread 
clinical acceptance for use in routine breast cancer detection and diagnosis. 
2.4 Neuropeptide Y receptor scintigraphy 
Neuropeptide Y (NPY) is a neurotransmitter that belongs to a family of 36 amino-acid-long 
peptides that also includes peptide YY and pancreatic polypeptide. In the central nervous 
system, the actions of NPY consist of stimulation of feeding behavior and inhibition of 
anxiety, while in the peripheral nervous system NPY regulates a variety of functions such as 
vasoconstriction, gastrointestinal motility and secretion, insulin release, and renal function 
(Koglin & Beck-Sickinger, 2004; Reubi, 2008). These effects are mediated by interaction with 
various metabotropic G protein-coupled NPY receptor subtypes (Y1, Y2, Y3, Y4, Y5, Y6), 
among which Y1, Y2, Y4, and Y5 have been well characterized.  
In contrast to other regulatory peptides, NPY has not often been associated with human 
cancer. However, a recent in vitro study, which included over 100 human breast cancer 
samples, reported that the NPY receptor, predominantly the Y1 subtype, was expressed in 
85% of primary carcinomas and 100% of lymph node metastases of receptor-positive 
primary tumors. These results are higher than those reported in a subsequent trial, in which 
the NPY(Y1) receptor was observed in only 69% of the primary breast tumor samples 
analyzed and at high density (>2,000 dpm/mg tissue) in only 66% of those samples. 
The recent development of receptor subtype selective NPY analogs, combined with novel 
strategies for the synthesis and radiolabeling of these analogs, has enabled progress in the 
construction of NPY receptor targeted radiopharmaceuticals that may be employed for 
breast cancer detection and diagnosis. Radiolabeling of NPY(Y1)-selective conjugates was 
initially achieved by exploiting the high tyrosine content of these derivatives which allowed 
for the oxidative incorporation of iodine-125 (125I). Although this represents a rapid and 
facile radiosynthetic method, it is also non-selective, allowing for the potential incorporation 
of 125I into residues that are involved in receptor binding. In order to address this limitation, 
subsequent radiolabeling techniques have employed photolabile protecting groups and 
bifunctional chelating agents (BFCA) (Zwanziger et al., 2008). 
Despite these advances in the field of NPY(Y1) receptor imaging, proof of principle remains 
to be established. In fact, in a recent study which utilized NMRI nu/nu mice bearing MCF-7 
tumors to analyze the biodistribution of the NPY(Y1)-selective peptide DOTA-[Phe7, Pro34] 
NPY radiolabeled with indium-111 (111In), tumor uptake of the conjugate was relatively low 
at all time points (30 minutes post-injection (p.i.) = 1.7 ± 0.5% injected dose per gram 
(%ID/g)). In addition, although the NPY(Y1) receptor is found in high density in 66% of in 
situ, invasive, and metastatic breast cancers, it is also present in both the lobules and ducts 
of normal breast tissue, which decreases the tumor-to-background ratio and degrades the 
overall image resolution. Thus, the suitability of radiolabeled NPY(Y1) receptors for the 
routine detection and diagnosis of breast cancer remains in question. 
2.5 Gastrin releasing peptide receptor (GRPr) sScintigraphy 
Gastrin releasing peptide (GRP) is a peptide hormone composed of 27 amino acids that, 
along with neuromedin C, are the cleavage products of a 148 amino acid preproprotein. 
GRP belongs to the bombesin-like (bombesin = BBN) family of peptides that regulates 
numerous functions in the enteric and the central nervous systems, including circadian 
rhythm, immune function, thermoregulation, satiety, gastrointestinal hormone release, 
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smooth muscle contraction, and epithelial cell proliferation (Knigge et al., 1984). These 
actions are mediated by binding to Gq/11 protein-coupled receptors of the bombesin family 
(BB1- Neuromedin B receptor, BB2- GRPr, BB3- Orphan receptor, BB4- BBN receptor) 
expressed in the pancreas, stomach, adrenal cortex, and brain, which activates the 
intracellular phospholipase C signal transduction cascade leading to inositol triphosphate 
(IP3) and diacylglycerol (DAG) generation, and subsequent intracellular calcium elevation 
(Gugger & Reubi, 1999; Smith et al., 2005). 
Of all the physiological effects of GRP, the most studied is the one related to cancer. 
Investigation into the role of GRP in cancer progression began with the observation in 1981 
that both cancer cell lines and primary human tumors can synthesize GRP as well as its 
amphibian analog BBN (Moody et al., 1981). Four years later, Cuttitta et al. demonstrated 
that GRP and BBN stimulate the growth of small cell lung cancer, and that this ability is part 
of an autocrine feedback mechanism that involves the interaction of these peptides with 
their receptors, which are expressed on the surface of tumor cells (Cuttitta et al., 1985). The 
mitogenic role of GRP and BBN in other cancers has since been established, including those 
of the lung, pancreas, prostate, central nervous system, and breast (Reubi, 2008). While the 
mechanism of growth stimulation does not appear to be constant for all carcinomas, it 
generally involves the transactivation and up-regulation of epidermal growth factor (EGF) 
receptors (Van de Wiele et al., 2000). 
Although GRPrs have been readily detected in various tumor cell lines, identification of 
these receptors in primary human tumors has proven to be more difficult. While the 
presence of GRPr proteins has not been conclusively established in either gastrointestinal or 
exocrine pancreatic carcinomas, both GRP mRNA and receptor proteins have been detected 
in neoplasms of the prostate and breast (Reubi, 2008). Expression of GRPrs in neoplastic 
epithelial mammary cells have been reported in approximately two thirds (62-71%) of all 
breast carcinomas, and in high density (>2,000 dpm/mg tissue) in 65% of these cases. In 
addition, all of the lymph node metastases from GRPr-positive primary breast carcinomas 
were positive for this receptor, whereas the surrounding lymphoreticular tissue was GRPr-
negative. Although GRPrs are present in both the ducts and lobules of nonneoplastic breast 
tissue, their heterogeneous distribution, coupled with the strong GRPr expression by 
primary breast carcinomas as well as metastatic sites, indicates that breast cancer may be 
effectively imaged using GRP and BBN analogs (Gugger & Reubi, 1999; Reubi, 2008). 
For over a decade, the feasibility of using radiolabeled BBN analogs to detect and diagnose 
GRPr-positive breast cancer has been investigated. The translation of these efforts into 
human subjects first occurred in 2000, with the publication of the results from the first 
human trial (Van de Wiele et al., 2000). In order to evaluate the diagnostic utility of 99mTc-
RP527, Van de Wiele et al. administered this agent to six patients with metastatic breast 
cancer prior to image acquisition (planar, SPECT). While low physiological uptake of 99mTc-
RP527 was observed in normal breast tissue, it did not affect the visualization of either the 
primary tumor or metastatic sites, which were successfully imaged in 4 out of 6 patients 
with tumor-to-background ratios of 1.7 to 3.4 and 2.6 to 7.2 at 1 and 6 hours p.i., 
respectively. Similar results were obtained by Scopinaro et al. in a 2002 trial which 
compared the diagnostic capacity of a 99mTc-labeled BBN analog with that of 99mTc-sestamibi 
in five patients with infiltrating ductal carcinoma (Scopinaro et al., 2002). Although the 
identification of metastatic sites was achieved with both agents, detection of the primary 
tumor was higher for 99mTc-BBN (100%) than for 99mTc-sestamibi (80%). This may be related 
to the higher affinity of BBN analogs for malignant breast tissue which often over-express 
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the GRPr, allowing for improved tumor-to-background ratios when compared with 99mTc-
sestamibi (1.4-2.3 vs. 1.0-1.8 at 5 minutes) (Scopinaro et al., 2002). While the results of these 
trials indicate that the detection/diagnosis of both primary breast cancer and metastatic 
sites can be achieved using radiolabeled BBN derivatives, the disadvantages demonstrated 
by these agents (moderate tumor-to-background ratios, hepatobiliary excretion) need to be 
addressed in order to recognize their full potential. 
2.6 GRPr-expressing T-47D human bBreast cancer cells 
The ability of radiolabeled BBN analogs to detect and diagnose both primary breast 
carcinomas and metastatic sites which express the GRPr, coupled with the expression of this 
receptor in 62-71% of breast cancer cases, has fueled continued interest in the development 
of BBN-based tumor targeting agents. In order to produce high quality SPECT images, 
radiotracer accumulation and residualization in GRPr-expressing cells must be maximized 
to optimize the contrast and hence the resolution of the resulting image. While there are 
other cell lines that express the GRPr in relative high numbers, our group and many others 
have used the T-47D human breast cancer cell line in a variety of studies to evaluate the 
therapeutic and diagnostic efficacy of potential radiopharmaceuticals. This differentiated 
cell line, with breast epithelial morphology, was derived from a metastatic pleural effusion 
originating from an infiltrating ductal carcinoma in a 54 year-old Caucasian patient (Lacroix 
& Leclercq, 2004; Engel & Young, 1978). The cell line is described as “luminal epithelial-like” 
with markers indicating its pre-metastatic state according to the EMT (epithelial-
mesenchymal transition) hypothesis for metastatic transformation. It has been shown that 
the GRPR is over-expressed on the surface of T-47D breast carcinoma cells while being 
absent from normal breast tissues (Giacchetti et al., 1990). This receptor has served as a 
target for a number of diagnostic and therapeutic strategies (Prasanphanich et al., 2007; 
Garrison et al., 2007; Parry et al., 2007; Biddlecombe et al., 2007; Guojun et al., 2008; Zhou et 
al., 2003; Ma et al., 2007). T-47D xenografts in mice have been used in preclinical 
investigations of a variety of diagnostic modalities (Giblin et al., 2006; Aliaga et al., 2004). 
 
T-47D Cell Line 
Cell Line Origin 
Female patient. Age = 54. 
Pleural effusion from an invasive 
ductal carcinoma. 
Acquisition Data Dr. Keydar, 1974 
In Vitro Invasion Positive (low) 
Estrogen Receptor Positive 
Progesterone Receptor Positive 
GRPr Positive (36,000 sites/cell) 
125I-Tyr4-BBN(7-14)NH2: Binding 
Capacity and Affinity 
9.7x10-13M/mg 
KD = 1 nM 
Table 2. T-47D Cell line characteristics (Giacchetti et al., 1990) 
3. Site-directed radiopharmaceutical composition 
The use of peptide-based bioconjugates in molecular investigations is common. Typically, a 
peptide is covalently modified with a bifunctional chelating agent (BFCA) capable of 
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complexing and stabilizing a radionuclide. Pharmacokinetic modifiers can be introduced 
between the peptide and the BFCA to fine-tune the biodistribution of the bioconjugate. The 
potential of using peptide-based site-directed radiopharmaceuticals for in vivo single-photon 
emission computed topography (SPECT) and PET imaging has recently become apparent 
(Sprague et al., 2007; Weiner & Thakur, 2005). 
 
 
Fig. 1. Schematic representation of a radiolabeled targeting vector for treatment of human 
disease. 
3.1 Bombesin targeting vectors 
Radiopharmaceuticals designed to target the GRPr employ modified analogs of bombesin, a 
tetradecapeptide initially isolated from the skin of the fire-bellied toad Bombina bombina in 
1971 (Reubi, 2008; Smith et al., 2003; Zhang et al., 2004). The amidated C-terminus sequence 
of seven amino acids (Trp-Ala-Val-Gly-His-Leu-Met-NH2), which is homologous to that of 
GRP (Table 3), is utilized for conjugate synthesis as a result of the fact that this sequence is 
sufficient for specific high affinity binding to the GRPr.  
 
GRP 
Val-Pro-Leu-Pro-Ala-Gly-Gly-Gly-Thr-Val-Leu-Thr-Lys-Met-Tyr-Pro-Arg-Gly-
Asn-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2 
BBN* 
Pyr-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Val-Gly-His-Leu-Met-NH2 
Pyr-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Phe-Met-NH2 
*Two distinct forms of BBN have been identified for the BB4 receptor subtype. 
Table 3. Amino Acid Sequence Comparison, GRP versus BBN (Smith et al., 2003) 
The utilization of radiolabeled receptor agonists for cancer detection, diagnosis, and 
treatment has traditionally been accepted due to the fact that agonists often undergo rapid 
internalization upon receptor binding and are subsequently residualized within the tumor 
cell for an extended period of time. The internalization mechanism for BBN-based agonists 
involves the endocytosis of the agonist/GRPr complex into clathrin-coated vesicles and 
endosomes. This is followed by migration to the perinuclear space where lysosomal 
entrapment of the agonist occurs, prolonging the residence time of agonist-bound 
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radioactivity in the target tissue. This allows for the accumulation of radioactivity in GRPr-
positive tissues, thereby facilitating breast cancer diagnosis and treatment (Van de Wiele et 
al., 2000). While a number of BBN-based agonists have been developed, in order to maintain 
a high binding affinity for the GRPr subtype, these analogs all contain the seven amino acid 
GRPr binding motif with limited substitution (Coy et al., 1988; Pomper & Gelovani, 2008). 
The production of radiopharmaceutial agents from these BBN(7-14)NH2 based compounds 
may be readily achieved using a variety of radiometal chelates. The resulting radiotracers 
have been demonstrated to retain high specific binding to the GRPr in a variety of human 
cancer cell lines, including those of the prostate, pancreas, and breast (Inhibitory 
Concentration at 50% (IC50) = 1-10 nM). 
3.2 Pharmacokinetic modification—“Linking groups” 
An important aspect in the design of new radiopharmaceuticals is the adjustment of the 
pharmacokinetic properties of an agent, which influence its biodistribution and clearance. 
These factors have a significant impact on the tumor-to-background ratio, and hence the 
diagnostic and therapeutic utility that will be exhibited by a radiotracer. While the GRPr 
binding motif is not generally modified during conjugate production, amendments to this 
basic sequence are commonly employed for a number of reasons including augmentation of 
conjugate resistance to degradation by plasma peptidases, alteration of the pharmacokinetic 
properties of the derivative, and facilitation of the radiolabeling procedure (Blok et al., 1999; 
Signore et al., 2001). 
Incorporation of an inert spacer group into a BBN-based radiopharmaceutical is an effective 
method of modifying both the physiochemical properties and the metabolic fate of the 
bioconjugate, improving both the residualization of radioactivity by GRPr-positive 
malignant cells and clearance of the radiotracer from the blood and non-target tissues 
(Pomper & Gelovani, 2008). Both length and charge of the spacer group influence the 
pharmacokinetic properties, GRPr binding affinity, and tumor uptake of the BBN analog. 
Addition of a peptide sequence such as polyglycine or polyserine can be used to augment 
the hydrophilicity of a conjugate, thereby enhancing renal clearance, while the incorporation 
of a simple hydrocarbon chain may be employed to increase its lipophilicity in order to 
prolong its residence time in the bloodstream. An alternative approach to reduce the 
circulatory clearance rate of an analog is the insertion of a polyethyleneglycol (Peg) linker, 
which slows the extraction of the conjugate by hepatocytes (Krause, 2002). In the case of 
BBN(8-14)NH2 based analogs, the incorporation of a tethering moiety between the receptor 
binding sequence and the radiometal complex influences not only the pharmacokinetic 
properties and renal retention of the resulting conjugate, but also the binding affinity and 
the degree of receptor-mediated analog uptake that is observed in GRPr rich tissues. In 
order to maintain a GRPr binding affinity that is similar to native BBN, the receptor binding 
sequence and the radiometal chelate must be separated by a distance of five or more atoms 
and the spacer sequence employed to serve this purpose must not introduce an extra 
negative charge at the N-terminus (Hoffman et al., 2001; Zhang et al., 2004). 
Additionally, a spacer group creates distance between the appended radiometal chelate and 
the receptor binding sequence, which promotes the biological integrity of the radiotracer 
(Pomper & Gelovani, 2008). As both the receptor binding sequence and the C-terminus are 
essential to the in vivo interaction between BBN-based conjugates and the GRPr, attachment 
of the tethering moiety occurs at the N-terminal tryptophan in position 8 (Trp8). Spacer 
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group selection is critical because the effect of side chain conjugation to the Trp8 residue is 
unpredictable. The attachment of some amino acid chains or other groups has been 
demonstrated to dramatically decrease the binding affinity of the BBN analog (Coy, et al., 
1988). To avoid this issue, glutamine is frequently appended to the Trp8 residue prior to the 
addition of the linker as its inclusion is not only compatible with maintaining high GRPr 
binding affinity, but also with reducing the renal retention of the resulting BBN(7-14)NH2 
conjugate (Hoffman et al., 2001). 
3.3 Radiolabeling techniques and bifunctional chelating agents (BFCAs) 
Radiolabeling may result in substantial alterations to both the lipophilicity and the charge of 
the radiopharmaceutical and has important consequences for both the biodistribution and 
the kinetic properties of the resulting agent (Blok et al., 1999; Signore et al., 2001). For 
instance, the introduction of a negative charge at the N-terminus of a BBN analog leads to a 
loss of binding affinity, while a positive charge augments it, resulting in the potential for 
increased accumulation in GRPr rich tissues. Radioisotope complexation to biologically 
active peptide based targeting vectors may be accomplished via either direct or indirect 
radiolabeling approaches (Stigbrand et al., 2008). While there are distinct advantages and 
disadvantages associated with each of these methods, the production of high specific 
activity products is essential to the generation of high resolution scintigraphic images. 
Direct radiolabeling is a relatively rapid, facile synthetic method that utilizes functional 
groups, such as sulfhydryls or thioethers, which are present within the peptide to complex 
the radioisotope. However, this technique often suffers from a lack of specificity as the 
location of radioisotope incorporation into the resulting radiopharmaceutical may involve 
functional groups within or near the receptor binding sequence. This can decrease the 
affinity of the conjugate for its receptor, resulting in diminished accumulation in target 
tissues, which reduces the resolution, and hence the diagnostic utility of the scintigraphic 
image that is produced. 
Indirect radiolabeling overcomes many of these difficulties by employing a bifunctional 
chelating agent (BFCA) to complex the radioisotope, providing distance between the metal 
chelate and the receptor binding sequence in order to preserve the biological activity of the 
radiopharmaceutical. BFCAs are designed not only to form stable, high yield complexes 
with metallic radionuclides, but also to covalently link these radioisotopes to the targeting 
vector. The BFCA may be conjugated to the targeting vector either prior to or subsequent to 
the radiolabeling procedure. In the pre-conjugation technique, synthesis of the BFCA-
radiometal complex occurs in advance of conjugation to the targeting vector. This method is 
employed when the BFCA-radionuclide complex can only be generated under harsh 
reaction conditions, such as extreme temperature or pH, which may destroy the receptor 
binding region of the molecule (Stigbrand et al., 2008). The preferred method of indirect 
radiolabeling is the post-conjugation approach as it represents an effective, one-step method 
of radiopharmaceutical synthesis in which the BFCA is directly conjugated to the targeting 
vector prior to radioisotope complexation. Ideally, only specific donor atoms of the BFCA 
will coordinate the radiometal to produce a high yield conjugate with both high receptor 
affinity and in vivo stability. In order to achieve a high degree of in vivo stability, the BFCA 
must impart both thermodynamic and kinetic inertness to the resulting radiometal complex. 
This serves to decrease not only the in vivo metabolism of the radiopharmaceutical but also 
the subsequent retention of these metabolites by non-target tissues such as the stomach, 
liver, and kidneys, thereby increasing the tumor-to-background ratio. 
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4. microSPECT imaging using technetium-99m-BBN agents 
Although a multitude of radioisotopes have been utilized in the development of diagnostic 
radiopharmaceuticals, 99mTc remains the most widely employed radionuclide in diagnostic 
nuclear medicine, accounting for approximately 85% of all nuclear medicine procedures 
performed (Smith et al., 2003). Technetium-99m is well suited for use as a radionuclide due 
to its ready availability via on site 99Mo/99mTc generator systems, ideal nuclear 
characteristics (half-life (t1/2) = 6.04 hours, gamma energy = 140.5 keV (89%), high specific 
activity), favorable dosimetry, and well-established labeling chemistries using a variety of 
BFCAs (Fischman et al., 1993; Smith et al., 2003 and 2005; Varvarigou et al., 2004). In 
addition, the chemistry of 99mTc is parallel to that of the therapeutic radioisotopes 186/188Re, 
allowing for the development of diagnostic/therapeutic radiopharmaceutical pairs. As such, 
the diagnostic agent may be employed in prescreening patients prior to therapy, which 
would provide valuable individual information regarding drug pharmacokinetics, receptor 
density, and dosimetry, potentially reducing or even eliminating unsuccessful 
radiotherapeutic regimens. 
While 99mTc can exist in a variety of oxidation states ranging from +7 to -1, it is most stable 
in the +7 state (i.e. TcO4-, pertechnetate). Lower oxidation states may be stabilized by 
complexation with numerous ligands, resulting in radiometal chelates that have 
coordination numbers between 4 and 9. While oxidation states below +4 are easily oxidized 
to the +4 state, 99mTc in the +5 and +6 states frequently undergoes disproportionation into 
the +4 and +7 states, respectively. However, the type of complex formed and its stability are 
highly dependent on labeling conditions, which include pH, BFCA, reducing agent, and 
concentration. Initially, 99mTc chemistry focused on the +5 oxidation state as it may be 
complexed using a broad range of thiol-, isonitrile-, or phosphine-containing chelates to 
produce compounds that are highly stable in aqueous media (Blok et al., 1999). However, it 
is often difficult to produce well-defined conjugates with high specific activity via direct or 
indirect radiolabeling techniques, due to the fact that the reduction of the disulfide bonds in 
the targeting vector or the ligand framework may occur as a consequence of the presence of 
excess reducing agent (Sn2+) in the labeling cocktail (Schibli & Schubiger, 2002). In addition, 
the resulting derivatives frequently suffer from significant in vivo hydrophobicity, 
prolonging their residence time in both the circulatory system and non-target tissues, which 
decreases the target-to-background ratio, and hence the resolution, of the resulting 
scintigraphic image, while simultaneously increasing the radiation exposure to the patient 
(Smith et al., 2003). 
Both of these issues have been addressed utilizing the organometallic tricarbonyl core, fac-
99mTc(CO)3, formulated in the late 1990s (Alberto et al., 1998). Although initially the fac-
[99mTc-(H2O)3(CO)3]+ precursor was obtained by direct carbonylation of the permetallate salt 
(Na[TcO4]) using sodium borohydride under atmospheric carbon monoxide pressure, a 
method was subsequently devised for the fully aqueous, normal pressure preparation by 
employing potassium boranocarbonate (K2[H3BCO2]) as both the reducing agent and the 
source of carbon monoxide (Alberto et al., 2001; Schibli & Schubiger, 2002). This method 
eliminates undesired disulfide bond reduction in the conjugates because excess reducing 
agent is destroyed prior to the radiolabeling procedure. The synthetic ease, high yield, 
excellent radiochemical purity,  reproducibility, and improved safety associated with this 
new method of radiolabeling using the tricarbonyl core spurred the development of a 
commercial kit (Isolink®) for [99mTc-(H2O)3(CO)3]+ preparation (Biersack & Freeman, 2007). 
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The remarkable kinetic and thermodynamic stability demonstrated by the [99mTc-
(H2O)3(CO)3]+ aqua ion in aerobic, aqueous solutions over a wide range of pH values is 
derived from two factors: 1) the shape of the 99mTc-labeled precursor, and 2) the oxidation 
state of 99mTc. The 99mTc(CO)3 metal core is compact, with an almost spherical shape, which 
if “closed” with an appropriate ligand system will form an octahedral coordination sphere 
that effectively protects the metal center against further ligand attack or reoxidation. 
Conversely, 99mTc(V)-complexes possess an “open” quadratic pyramidal structure, which is 
prone to ligand attack and/or protonation often resulting  in decomposition of the original 
complex (Schibli & Schubiger, 2002). In addition, 99mTc(I) has a low spin d6 electron 
configuration that is responsible for the octahedral shape of these complexes, endowing 
them with large crystal field stabilization energies in the presence of strong field ligands 
such as CO, further contributing to the kinetic and the thermodynamic stability of these 
compounds. Unlike the CO ligands in the aqua ion, the water ligands are not π-electron 
acceptors and as a result their binding to the metal center is not stabilized by synergic 
bonding. This accounts for the substitution lability of these ligands which can undergo facile 
exchange reactions with a number of donor groups including amines, thioethers, 
phosphines, and thiols (Jones & Thornback, 2007). The ease of these reactions contributes to 
the excellent labeling efficiencies exhibited by the [99mTc-(H2O)3(CO)3]+ precursor, which 
results in the production of metallated conjugates with remarkable in vitro and in vivo 
stability against serum-based proteins and superior uptake and retention when compared 
with 99mTc(V)- agents. 
In recent studies, we have evaluated conjugates of the type DPR-Y-BBN(7-14)NH2 where 
DPR = 2,3-diaminopropionic acid (DPR), and Y= GSG or SSS (Retzloff et al., 2010) that when 
radiolabeled with  fac-[99mTc-(H2O)3(CO)3]+ produced metallated conjugates 99mTc-(CO)3-
DPR-Y-BBN(7-14)NH2 in  very high yield (~90%) (Figure 2)  These products demonstrated in 
vitro stability in excess of 24 hours as monitored by reverse phase-high performance liquid 
chromatography (RP-HPLC), with no observable degradation or transchelation to inherent 
functional donor atoms present in either histidine solution (1 mM) or human serum 
albumin. 
In competitive radioligand binding assays against 125I-[Tyr4]-BBN(7-14)NH2, the standard 
for the evaluation of GRPr specific binding, these derivatives demonstrated very high 
affinities for the GRPr, with IC50 values of 8.1 ± 1.3 nM for Y = GSG, and 5.9 ± 0.8 nM for Y = 
SSS in the T-47D cell line (Retzloff et al., 2010). The internalization and externalization 
(trapping) of the 99mTc-(CO)3-DPR-Y-BBN(7-14)NH2 derivatives, when assessed in T-47D cell 
lines showed that the apex of internalization occurred between 45 and 120 minutes, when 
uptake levels reached 80-88% of all cell-associated radioactivity in the T-47D cell line. This 
level of internalization remained relatively constant for subsequent time points, with no 
significant efflux of radiotracer observed over a 90-minute period.  
Results obtained from biodistribution studies in SCID mice bearing human T-47D 
xenografted tumors suggested that analog size and lipophilicity strongly influence in vivo 
pharmacokinetic behavior. While the 99mTc-(CO)3-DPR-Y-BBN(7-14)NH2 derivatives were 
eliminated primarily via the renal-urinary system, both the rate and the extent of  clearance 
was affected by the DPR BFCA and the amino acid spacer sequence of the derivative. The 
prompt elimination of the DPR analogs from the body, where Y = GSG or SSS, can be 
attributed to the small size and hydrophilic nature of both the DPR BFCA and the amino 
acid linkers which served to mitigate the lipophilic character of the 99mTc(CO)3 metal core. 
As a result of this clearance pattern, these 99mTc-(H2O)(CO)3-DPR-Y-BBN(7-14)NH2 analogs 
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demonstrated consistently lower levels of background radioactivity in non-target tissues, 
such as the liver and the gastrointestinal tract. In addition to aiding in their prompt 
elimination via the renal-urinary pathway, the small size and hydrophilic nature of the DPR 
derivatives containing amino acid linkers allowed for the rapid penetration of these 
conjugates into GRPr-positive target tissues, as evidenced by their comparatively high levels 
of uptake by both  GRPr-expressing pancreatic and tumor tissues. Tumor uptake and 
retention in T-47D xenografted breast cancer tumors were 2.3-2.4 ± 0.4-0.8% ID/g (Y = GSG) 
and from 2.4-3.7 ± 0.7-1.8% ID/g (Y = SSS) at 1 hour p.i., respectively. 
 
 
Fig. 2. 99mTc-(CO)3-(H2O)-DPR-GSG-BBN(7-14)NH2 (A) and 99mTc-(CO)3-(H2O)-DPR-SSS-
BBN(7-14)NH2 (B) conjugates. 
 
 
Fig. 3. microSPECT/MRI/CT imaging of 99mTc-(H2O)3(CO)3-DPR-SSS-BBN(7-14)NH2 after 
24 h p.i.  
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Due to each rapid elimination from non-target tissues via the renal-urinary excretion 
pathway and moderate accumulation and retention in tumor tissue, 99mTc-(H2O)(CO)3-DPR-
Y-BBN(7-14)NH2 conjugates were evaluated for microSPECT imaging in T-47D tumor-
bearing SCID mice at 24 hours p.i.(Figure 3). These conjugates produced favorable tumor-to-
background ratios, which allowed for clear visualization of tumor tissue, despite some level 
of background radioactivity. Although the location and intensity of this background 
radioactivity fluctuated slightly among these conjugates, the kidneys and the 
gastrointestinal tract were consistently the predominant sources of radioactivity at the time 
of imaging. Despite these subtle differences in biodistribution, clear identification of tumor 
tissue was readily achieved with both derivates, supporting the hypothesis that radiolabeled 
99mTc(I)-BBN conjugates may be employed to diagnose GRPr-expressing breast cancers.  
5. microPET imaging with copper-64-BBN conjugates 
While a variety of diagnostic imaging techniques exist for identifying breast cancer, low-
dose mammography is still considered to be the most accurate and dependable procedure 
(Prasad & Houserkova, 2007). Still, digital mammography is most accurate in women under 
50, with low-density breast, who have either not entered or recently passed through 
menopause (Pisano et al., 2005). PET imaging using FDG (18F-fluorodeoxyglucose) has been 
an effective technique for diagnosis of primary breast cancer and benefited from PET 
imaging devices designed specifically for breast imaging. While FDG-PET was able to 
identify tumors in the breast, a high false-positive rate, 87%, limits its wide-spread use. 
(Kaida et al., 2008). Thus there is a need to develop diagnostic modalities with increased 
specificity for malignant breast tissues and capable of overcoming these limitations. 
Targeting a unique physiological manifestation of breast malignancy, such as over-
expression of an extracellular receptor with a diagnostic radionuclide, might be a procedure 
capable of imaging tumors of the breast with higher resolution and lower false-positive 
rates. 
Copper-64 is one of few radionuclides possessing physical properties that allow for medical 
imaging and therapy (Nijsen et al., 2007). The utility of 64Cu (t1/2 = 12.7 h, cyclotron 
generated as 64CuCl2) results from its diverse decay profile. Electron capture, with 
corresponding gamma emission at 1346 keV, accounts for 41% of the decay profile for 64Cu. 
This is accompanied by emission of a β- particle (40%, 190 keV) and a positron (β+, 19%, 278 
keV). The degree of β+ decay is sufficient for PET imaging in vivo and has been extensively 
investigated. Moreover, 67Cu-containing radiopharmaceuticals possess therapeutic potential 
and provide in vivo pharmacokinetic profiles nearly identical to 64Cu-containing drugs 
(Blower et al., 1996). 67Cu has ideal physical characteristics that are well-suited for 
radionuclide therapy (β-, 100%, 121 keV, t1/2 = 62 h) (Voss, et al., 2007). As such, 64Cu can be 
used as a dose-determinant indicator in 67Cu-based therapeutic regimens.  
While the physical properties of copper are well-suited for use in radiopharmaceuticals, the 
metabolism and physiological properties of copper in the human body present a challenge 
to the development and wide-spread use of copper-containing radiopharmaceuticals. 
Ideally, site-directed radiopharmaceuticals accumulate at the target site quickly with little 
accumulation in non-target tissues and rapidly clear non-target tissues after administration. 
Hence, hepatobiliary clearance of radiopharmaceuticals is much less desirable to 
renal/urinary clearance. Since the liver is the anatomical location of copper metabolism, the 
stability of the copper chelate in a 64Cu-containing radiopharmaceutical under physiological 
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conditions is very important (Wadas et al., 2007). Increasing the stability of copper 
complexes in vivo has been a major focus in the field of nuclear medicine for some time (Di 
Bartolo et al., 2001 and 2006; Gasser et al., 2008; Kukis et al., 1993; Voss et al., 2007; Pippin et 
al., 1991; Geraldes et al., 2000; Wieghardt et al., 1982; van der Merwe et al., 1985; 
Prasanphanich et al., 2007; Soluri et al., 2003; Maina et al., 2005; Monstein et al., 2006; Sun & 
Chen, 2007) as the development of stable copper complexes will allow for a variety of 
copper-based diagnostic and therapeutic strategies.  
Recent work in the field of copper radiochemistry has produced very promising results. A 
majority of the work has focused on synthesis of new ligand frameworks to chelate copper 
in a multi-dentate fashion to prevent loss of the Cu2+ ion under in vivo conditions. Cross-
bridged TETA (1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetracetic acid) derivatives, such as 
4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane (CB-TE2A) and 1-N-(4-
aminobenzyl)-3,6,10,13,16,19-hexa-aza-bicyclo-[6.6.6]eichosane-1,8-diamine (SarAr), have 
shown increased copper-complex stability in vivo versus the TETA and DOTA (1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid) chelators (Garrison et al., 2007; Di Bartolo et 
al., 2001 and 2006). Additionally, derivatives of the triazacyclononane macrocycle have 
produced improved stability of copper complexes (Prasanphanich et al., 2007). Pippin et al., 
have shown that complexes of Cu(II) with NOTA (1,4,7-triazacyclononane-1,4,7-triacetic 
acid) are more inert towards isotopic exchange with 67Cu than DOTA or TETA (Pippin et al., 
1991). Recent work by Gasser, et al., demonstrated a 2-[4,7-bis(2-pyridylmethyl)-1,4,7-
triazacyclononan-1-yl] acetic acid (PMCN) bifunctional chelator containing the 64Cu 
radionuclide (Gasser et al., 2008). Recently, we have reported on the superior microPET 
imaging quality of NOTA bifunctional chelator over that of the DOTA using 64Cu in a 
GRPR-positive human prostate cancer mouse model (Prasanphanich et al., 2007). Previous 
investigations have reported a highly stable complex consisting of NOTA and divalent 
copper (Kukis et al., 1993; Geraldes et al., 2000; Wieghardt et al., 1982). Also reported are 
biomolecules conjugated with NOTA and chelating 64Cu. Interestingly, one investigation 
reported a crystal structure of [CuCl(TACNTA)-], or [CuCl(NOTA)-], with a pentadentate 
NOTA in which one carboxylate arm of the triazacyclononane macrocycle is not involved in 
the coordination of copper(II) (van der Merwe et al., 1985). This implies that occupation of 
this non-chelating carboxylate of NOTA, as in our bifunctional NO2A, may not alter the 
native structure of the Cu-NOTA complex. 
 We have recently evaluated 64Cu-NO2A-8-Aoc-BBN(7-14)NH2 radiopharmaceutical (Figure 
4) to be used as a PET targeting agent for primary or metastatic breast cancer disease 
(Prasanphanich et al., 2009). In this study, we were able to prepare high specific activity 
64Cu-NO2A-8-Aoc-BBN(7-14)NH2 conjugate in very high radiochemical yield and to 
evaluate the 1) targeting capacity of 64Cu-NO2A-8-Aoc-BBN(7-14)NH2 for GRPr-positive 
tissues in vivo; 2)  particular routes of clearance; and 3) extent of retention of 
radiopharmaceutical in radiosensitive tissues. 
A number of in vitro assays were used to evaluate the uptake and affinity of 64Cu-NO2A-8-
Aoc-BBN(7-14)NH2 for the GRPr in T-47D human breast cancer cells. Competitive binding 
displacement assays using 125I-[Tyr4]-BBN(7-14)NH2, as the radioligand were used to 
quantify the relative binding affinity of Cu-NO2A-8-Aoc-BBN(7-14)NH2 for GRPrs located 
on the surface of T-47D cells. The concentration of Cu-NO2A-8-Aoc-BBN(7-14)NH2 needed 
to inhibit 125I-[Tyr4]-BBN(7-14)NH2 binding by 50% was determined to be 7.56  2.23 nM. 
The rate at which cell-associated radioactivity was internalized within the T-47D cells was 
also measured. After incubating T-47D cells in media containing 64Cu-NO2A-8-Aoc-BBN(7-
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14)NH2 for 45 min, nearly 90% of all cell-associated radioactivity had internalized. This 
remained nearly constant for subsequent time points. The externalizaton of 64Cu-NO2A-8-
Aoc-BBN(7-14)NH2 from T-47D cells was measured by removing cells from conjugate-
containing media after 45 min and washing them to remove all surface-bound radioactivity. 
No significant efflux of radiotracer was observed over the 90 min period.  
 
 
Fig. 4. 64Cu-NO2A-8-Aoc-BBN(7-14)NH2 conjugate. 
Results obtained from biodistribution studies in SCID mice bearing human T-47D 
xenografted tumors suggested uptake in GRPr expressing tissues was receptor mediated. 
The average uptake and retention of conjugate in T-47D xenografted tumors at 1, 4, and 24 h 
p.i. were 2.27  0.08, 1.35  0.14, and 0.28  0.07% ID/g. The primary mode of excretion for 
this conjugate was the renal-urinary excretion pathway. A receptor blocking assay in which 
BBN(1-14)NH2 was administered 15 min prior to targeting vector in T-47D tumor-bearing 
mice showed a significant decrease in the accumulation of 64Cu-NO2A-8-Aoc-BBN(7-14)NH2 
in tumor tissue. For example, uptake/accumulation of 64Cu-NO2A-8-Aoc-BBN(7-14)NH2 
conjugate was reduced to 0.580.10% ID/g (1 h p.i.) with the addition of the blocking agent 
to the study. Furthermore, in the blocking assay, the degree of urinary excretion increased to 
82  18% ID and suggests that the radioactivity detected in the intestines were at least 
partially the result of a receptor-mediated process located along the lower gastrointestinal 
tract and not solely a function of hepatobiliary excretion. Additionally, accumulation of 
radiotracer in pancreatic tissue and tumors was significantly decreased in this blocking 
experiment, suggesting that the 64Cu-NO2A-8-Aoc-BBN(7-14)NH2 conjugate is intact and 
that GRPr-mediated binding is facilitating uptake in the tissues. 
As a result of optimal uptake and retention of 64Cu-NO2A-8-Aoc-BBN(7-14)NH2 in T-47D 
xenografted tumor, microPET/MicroCT/microMRI multimodal imaging experiments were 
conducted in tumor-bearing mice (Figure 5). A SCID mouse bearing T-47D xenografted 
tumors on the left and right hind flanks underwent microMR and microPET/CT imaging 24 
h following injection with 5.1 mCi of 64Cu-NO2A-8-Aoc-BBN(7-14)NH2. Anatomical 
structures observed via microPET imaging were consistent with pharmacokinetic data 
obtained from in vivo experiments. For example, tumors, pancreas, liver and kidneys, to a 
lesser extent, were clearly identifiable via microPET imaging analysis. Analysis of MRI data 
indicated small necrotic regions in the xenografted tumors as evident by increased water 
diffusivity. Observable in the microPET data were regions of reduced intensity that 
correlated well to these necrotic regions of the tumors. Additionally, the liver is observed to 
lack a uniform intensity. The drop in intensity correlates to the separation between the 
median and left lobes of the liver. The identification of such fine structures in the microPET 
data is a goal of diagnostic nuclear medicine. High-resolution imaging may aid in 
identifying structural boundaries as well as possible malignant sites. 
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Fig. 5. In vivo microPET/CT and microMRI images of a T-47D tumor-bering mouse 24 h 
after 5.1 mCi tail vein injection of 64Cu-NO2A-8-Aoc-BBN(7-14)NH2 conjugate. (A) 
MicroPET/MRI fusion coronal image. (B) MicroPET/CT fused coronal image showing 
specific uptake of 64Cu-NO2A-8-Aoc-BBN(7-14)NH2 conjugate. (C) Proton density-weghted 
microMRI coronal image. (D) An axial cross section of microPET/CT images showing 
functional image of tumor uptake. (E) The corresponding high-resolution T2-weighted 
microMRI axial image correlating anatomical features of the xenografted tumors to (D). 
6. Fluorescence molecular imaging using alexa fluor 680-BBN conjugates 
Alternative optical imaging technologies such as fluorescence molecular tomography are 
emerging as new and exciting molecular imaging tools for diagnosis of human disease 
(Montet et al., 2006; Young & Rozengurt, 2005; Pu et al., 2005). Studies show that the high-
throughput signal afforded by fluorescence imaging might offer an alternative to traditional 
tomographic imaging by alleviating many of the imaging artifacts seen in imaging systems 
of this general type (Weissleder & Ntziachristos, 2003; Zacharakis et al., 2005; Kwon et al., 
2005). Therefore, design and development of new site-directed, fluorescent, targeting 
vectors for dynamic optical imaging of human cancers holds some significance. 
Monet and co-workers have described a new peptide-nanoparticle conjugate based upon 
bombesin that may be potentially useful for imaging pancreatic ductal adenocarcinoma. 
They reported the ability of this new conjugate to specifically target GRPrs expressed on 
normal pancreatic tissue with minimal accumulation in normal and surrounding tissues. 
Furthermore, the utility of this new conjugate to be used as a dual modality MRI contrast 
agent was shown in vivo in T2 weighted MR images of rodents bearing MIA-PaCa2 
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pancreatic tumors (Montet et al., 2006). This study well demonstrates the potential of dual-
modality imaging for diagnosis of human cancers. Young and co-workers have recently 
described the use of quantum dots conjugated to bombesin to successfully image living 
mouse Swiss 3T3 and Rat-1 cells in vitro (Young & Rozengurt, 2005) and Pu et al.,  have 
described a new Cypate-bombesin Peptide Analogue Conjugate (Cybesin) that has potential 
use as a prostate tumor receptor-mediated contrast agent (Pu et al., 2005). All of these 
studies provide either in vivo or in vitro evidence for production of fluorescence-based 
targeting vectors of bombesin for early detection of human cancers. In addition, fluorescence 
molecular tomography shows advantages as a relatively low cost, noninvasive procedure 
that utilizes highly sensitive, non-ionizing probes for tissue targeting. 
To complement our work using technetium-99m and copper-64 tagged bombesin tracers to 
image T-47D breast cancer cells, we developed a new non-radioactive, fluorescent probe 
based upon BBN having high tumor uptake and optimal pharmacokinetics for specific 
targeting and optical imaging of the same cell line. In this study, we have developed a 
conjugate of bombesin having very high affinity for the GRP-receptor holding an N-terminal 
fluorescent tag that might be useful in determining the diagnosis and disease progression of 
estrogen receptor positive (ER+) breast cancer. Targeting ER+ breast cancer cells via a 
targeting vector bearing a fluorescent label is a viable alternative to traditional radiolabeled 
conjugates of this general type. 
The new Alexa Fluor 680-GGG-BBN(7-14)NH2 conjugate (Figure 6) was conveniently 
synthesized by solid phase peptide synthesis of the parent BBN ligand followed by N-
terminal conjugation of the active succinimidyl ester of the Alexa Fluor molecule (Ma et al., 
2007). This conjugation technology provides a mechanism for appending large molecular 
weight molecules having inherent fluorescent properties to either the N-terminal primary 
amine or the epsilon primary amines of lysine-containing peptides or antibodies to produce 
stable conjugates for dynamic in vivo optical imaging. Less-reactive amidated C-termini, 
however, do not readily react with succinimidyl esters, making this a very selective 
conjugation method. In our hands, AF 680-GGG-BBN(7-14)NH2 conjugate was stable at 
temperatures of -80 ºC for periods extending 6 months. Other Alexa Fluor® 680 compounds 
of this general type designed and developed in our laboratory have demonstrated similar 
stability profiles.  
 
 
Fig. 6. AF 680-GGG-BBN(7-14)NH2 conjugate.  
In order to assess the binding affinity of the Alexa Fluor 680-GGG-BBN(7-14)NH2 conjugate 
for the GRPr, in vitro competitive cell-binding assays were performed on T-47D breast 
cancer cells using 125I-[Tyr4]-BBN(7-14)NH2 as the displacement radioligand. This new 
peptide conjugate demonstrated very high affinity for the GRPr in T-47D breast cancer cells, 
exhibiting an IC50 value of 7.7 ± 1.4 nM.  
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Figure 7 summarizes the results of studies to assess the degree of uptake, internalization, 
and blocking of the Alexa Fluor-GGG-BBN(7-14)NH2 conjugate in T-47D breast cancer cells 
via confocal fluorescence microscopy. Assessment of the degree of AF 680-GGG-BBN(7-
14)NH2 conjugate associated with the cells after a 40 min incubation period was evaluated 
following a cell wash with pH 7.4 incubation media. Results of these studies clearly indicate 
the effectiveness of AF 680-GGG-BBN(7-14)NH2 to specifically target the GRPr. To assess 
receptor-mediated internalization of AF 680-GGG-BBN(7-14)NH2 conjugate, surface-bound 
conjugate was removed using pH 2.5 (0.2 M acetic acid and 0.5 M NaCl) buffer. After the 
acid wash, much of the conjugate remained internalized within the cells. In vitro blocking 
studies, in which high levels of BBN(1-14) were administered to the cells prior to the AF 680-
GGG-BBN(7-14)NH2 conjugate, reduced the uptake/retention in normal GRPr-expressing T-
47D cells. This illustrates the high affinity and selectivity of this conjugate for GRPrs over-
expressed on T-47D breast cancer cells. In fact, there is little or no indication of fluorescent 
signal associated with the cells following the blocking experiment.  
 
 
Fig. 7. Confocal fluorescence photomicrograph of internalized uptake of Alexa Fluor 680-
GGG-BBN(7-14)NH2 in human T-47D breast cancer cells (left). Confocal fluorescence 
photomicrograph of blocked uptake of Alexa Fluor 680-G-G-G-BBN(7-14)NH2 in human T-
47D breast cancer cells by wild-type BBN(1-14).  
To assess the in vivo uptake of the Alexa Fluor conjugate, we have evaluated AF 680-GGG-
BBN(7-14)NH2 in rodents bearing human T-47D cancer cell xenografted tumors. In this 
study, dynamic optical imaging studies of T-47D breast cancer tumor xenografts in rodent 
models demonstrated the effectiveness of AF 680-GGG-BBN(7-14)NH2 to specifically target 
GRPr-expressing cells in vivo. Montet and co-workers have demonstrated the effectiveness 
of fluorescent bombesin conjugates to effectively target implanted tumors of the pancreas 
(Montet et al., 2006). However, the effectiveness of imaging was only demonstrated using 
excised pancreatic/tumor tissue. Our more recent investigations have indicated specific 
uptake of conjugate in human tumor tissue (Figure 8a) in xenografted rodent models. Some 
degree of uptake was also observed in collateral tissue of the abdomen. This, however, is not 
entirely unexpected due to the hydrophobic nature of the high molecular weight targeting 
vector. Blocking investigations (Figure 8b), in which BBN(1-14) was used to saturate the 
GRPr prior to administration of AF 680-GGG-BBN(7-14)NH2, showed little or no fluorescent 
signal associated with tumor tissue. To complement and verify the presence of GRPr-
www.intechopen.com
 Breast Cancer – Recent Advances in Biology, Imaging and Therapeutics 
 
296 
expressing tumors, magnetic resonance imaging was performed (Figure 8c and 8d). These 
studies further demonstrate the high degree of selectivity and affinity of AF 680-GGG-
BBN(7-14)NH2 conjugate for the GRPr. 
 
 
Fig. 8. In vivo uptake and blocking experiment of Alexa Fluor 680-GGG-BBN(7-14)NH2 in 
SCID mice bearing human T-47D breast cancer cell xenografts. Xenogen fluorescence images 
of mice with (A) normal uptake and (B) blocking assay. Magnetic resonance images of cross 
sections through tumors for (C) normal uptake and (D) blocking assay.  
7. Conclusion 
The clinical successes of Octreoscan® have paved the way for exploration and radiolabeling 
of biologically-active peptides for targeted molecular imaging and peptide receptor 
scintigraphy of receptors that are highly expressed on specific human tumors. This book 
chapter has focused primarily upon those peptides that are potentially useful for molecular 
imaging of human breast cancer. Specifically, our research investigations have focused 
primarily upon targeting GRPrs with truncated analogues of BBN peptide, as these 
receptors tend to be expressed in very high numbers on the surface of breast cancer cells. 
However, there are other cancer types that also express regulatory peptide receptors in very 
high numbers, making possible early diagnosis and staging of primary and metastatic 
disease for these cancers as well. More importantly, continued research efforts toward 
development of thermodynamically stable, kinetically inert radiolabeled peptides for 
specific targeting of receptors that are highly expressed on the surfaces of human cancer 
cells creates the opportunity to use peptide receptor targeted radiotherapy as a highly 
selective treatment strategy for tumor targeting of breast cancer and many others, or as a 
mechanism for this treatment strategy to complement traditional, clinically-useful 
chemotherapeutic regimens of treatment. 
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8. Future work 
Until now, the molecular basis for GRPr-targeted diagnosis or therapy of receptor-positive 
neoplastic disease has primarily focused upon targeting receptor over-expression using 
radiolabeled agonist ligands with inherent internalizing capability. However, recent reports 
by Nock et al., show compelling evidence that radiopharmaceutical design and 
development based upon antagonist-type ligand frameworks bear reexamination (Nock et 
al., 2003 and 2005). Antagonist ligands are presumably not internalized, and therefore are 
not expected to residualize as effectively in tumor tissue when compared to agonist-based 
ligand frameworks. Studies using 99mTc-Demobesin1 ([99mTc-N40-1,bzlg0,D-Phe6,Leu-
NHEt13,des-Met14]BBN(6-14)) demonstrated very high affinity and selectivity for the GRPR 
with pronounced accumulation and retention of radioactivity in human tumor xenografts in 
rodents (Nock et al., 2003 and 2005). In addition, Maecke and co-workers have begun 
investigating another antagonist-like targeting vector, [DOTA-4-amino-1-carboxymethyl-
piperidine-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2], having high selectivity for the 
GRPr (Mansi et al., 2009 and 2011). Therefore, selective targeting of specific receptor 
subtypes expressed on the surfaces of primary or metastatic breast cancer tissues with new 
and improved radiolabeled antagonists might provide a new avenue for earlier diagnosis 
and staging of patients presenting with disease. 
In addition, we should point out that discussions herein have only considered monomeric 
peptide targeting vectors for molecular imaging of breast cancer tissue. It is important to 
note that the clinical utility of monomeric radiolabeled peptides can be limited by a 
number of factors including receptor density, binding affinity, and pharmacokinetics. For 
example, high-quality, high tumor-to-background PET or SPECT images require a high 
degree of receptor expression on tumor cells as compared to normal, collateral tissue. For 
these reasons, multimeric or multivalent peptide probes have recently become a new 
avenue for diagnostic molecular imaging tumors expressing either singly- or multi-
targetable receptors. Continued design and development of multimeric or multivalent 
peptides capable of targeting multiple receptor subtypes highly expressed on human 
cancers could do much to improve image resolution and contrast, all but eliminating the 
high false-positive rates and non-target uptake that oftentimes limits some of the 
clinically-approved radiopharmaceuticals from widespread usage for diagnosis of 
malignant tissues. 
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